Next Article in Journal
Multifunctional Silver Nanoparticles Based on Chitosan: Antibacterial, Antibiofilm, Antifungal, Antioxidant, and Wound-Healing Activities
Previous Article in Journal
Bile Acid Regulates Mononuclear Phagocytes and T Helper 17 Cells to Control Candida albicans in the Intestine
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Emerging Animal-Associated Fungal Diseases

by
Julia Eva Carpouron
1,2,
Sybren de Hoog
3,
Eleni Gentekaki
1,2 and
Kevin David Hyde
1,4,5,*
1
Center of Excellence in Fungal Research, Mae Fah Luang University, Chiang Rai 57100, Thailand
2
School of Science, Mae Fah Luang University, Chiang Rai 57100, Thailand
3
Centre of Expertise in Mycology, Radboud University Medical Centre/Canisius Wilhelmina Hospital, 6525 GA Nijmegen, The Netherlands
4
Institute of Plant Health, Zhongkai University of Agriculture and Engineering, Haizhu District, Guangzhou 510225, China
5
Mushroom Research Foundation, 128 M.3 Ban Pa Deng T. Pa Pae, A. Mae Taeng, Chiang Mai 50150, Thailand
*
Author to whom correspondence should be addressed.
J. Fungi 2022, 8(6), 611; https://doi.org/10.3390/jof8060611
Submission received: 8 March 2022 / Revised: 9 May 2022 / Accepted: 12 May 2022 / Published: 8 June 2022

Abstract

:
The Global Action Fund for Fungal Infections (GAFFI) estimates that fungal diseases kill around 150 people each hour, and yet they are globally overlooked and neglected. Histoplasma and Talaromyces, which are associated with wildlife, cause systemic infections that are often lethal in patients with impaired cellular immunity. Dermatophytes that cause outbreaks in human hosts are often associated with domesticated animals. Changes in human behavior have been identified as a main cause of the emergence of animal-associated fungal diseases in humans, sometimes caused by the disturbance of natural habitats. An understanding of ecology and the transmission modes of causative agents is therefore essential. Here, we focus on fungal diseases contracted from wildlife and domesticated animals, their habitats, feces and carcasses. We discuss some basic fungal lifestyles and the risk of transmission to humans and illustrate these with examples from emerging and established diseases.

1. Introduction

Fungal diseases affect around one billion people annually resulting in over 1.5 million deaths [1,2]. Since the mid-20th century, a global rise in fungal infections and associated deaths has been noted. In recent years, several new and known fungal infections have emerged in immunocompromised and other long-term patients and in the human population as a whole [3,4]. Although some intrinsic characteristics of fungi contribute to the emergence of diseases [5], recent scenarios have mainly been associated with our modern activities, including the widespread use of medication (e.g., corticosteroids), urbanization, domestication, increase in population, tourism, migration and accelerated climate change [6,7,8,9,10]. Several of these emergent fungal infections have been described as zoonoses. Animals have been construed as the main contributors to infectious human diseases, representing 75% of all emerging infections [11]. Nonetheless, this fraction does not separate true animal pathogens from environmental pathogens that thrive on fecal matter and decaying animal bodies. This is a considerable oversight, as many emergent infectious fungi have an environmental reservoir with the capacity to invade animal hosts, including humans [3,12,13]. For instance, Talaromyces marneffei, an ascomycete infecting over 50,000 HIV-positive patients yearly, has been linked to bamboo rats and their habitats [14,15,16,17,18]. However, animals should not be falsely accused, our modern activities may have more impact, encroaching into wild animals’ habitats and domesticating them as pets represents a larger threat to public health [19]. In this context, we provide an update on the terminology and trends of fungal diseases emerging in humans, related to animals. For each category of fungus, we examine and compare the mode and likelihood of transmission to humans.

2. Terminology for Animal-Associated Fungal Infections

Several terms are used to refer to infectious diseases associated with animals. “Zoonosis” and “sapronosis” have often been used with variable and overlapping meanings by different authors [20,21]. The World Health Organization (WHO) officially describes zoonoses as infections naturally transmitted between vertebrate animals and humans. The term thus does not distinguish whether “true” pathogens or opportunists are involved [21,22,23]. Pathogens are adapted to and can complete their life cycle in a mammalian host, whereas opportunists inhabit environmental niches but are also able to survive in animal hosts. When an opportunist, acquired from a non-living source such as soil, decaying plant material or feces, causes infection and/or an outbreak, the latter is referred to as a sapronosis [22]. None of the fungi are dependent on vertebrate hosts, but they have increased fitness if they use a mammal in any stage of their life cycle. Sapronotic agents occasionally infect humans or other animals without showing any specialized adaptation to their host [24,25,26]. Fungi that have double life cycles with stages in both the environment and an animal host are known as environmental pathogens. These live as saprobes, but once inside a warm-blooded vertebrate, they display a specialized invasive phase adapted to the host [22,27]. Following infection, environmental pathogens can be dispersed in the environment through defecation (e.g., Histoplasma capsulatum) [28] or potentially escape the host’s body upon death (e.g., Coccidioides immitis) [22]. On the other hand, opportunistic fungi are non-transmissible among hosts, and upon death of the host, the fungus dies as well [22]. Environmental pathogens, zoonotic agents and sapronotic agents differ significantly in their life cycle, target population and clinical symptoms, and a clear distinction between them is important [22,26] (Figure 1).

3. Direct versus Indirect Transmission—Should We Fear One More than the Other?

Among other factors, the emergence of an infectious disease depends on the opportunity of transmission, and thus the emergence is dependent on transmission mode [30]. Two modes of transmission are recognized in infectious diseases including zoonoses: direct and indirect. Skin contact, scratches and bites constitute examples of direct transmission from an infected animal to a human host [20]. It is a highly efficient and exclusive mode of transmission in the spread of Sporothrix brasiliensis by cats. Indirect transmission occurs when pathogens shed in the environment by an infectious host are acquired by a new host [31,32]. The latter type of transmission involves vehicles for dispersal, such as air, water, food or an animal vector [20]. For instance, bats are vectors of Histoplasma capsulatum, as they actively carry and spread the fungus during long-distance flights. When comparing the two modes of transmission, indirectly transmitted pathogens are generally more successful long-term spreaders. Indeed, indirect transmission often involves extensive environmental dissemination. This is particularly true for dimorphic fungi and fungi producing spores that can persist outside the host for extended periods, thus increasing the likelihood of transmission [30]. Persistence in the environment also increases the probability of spillover events resulting in infections of not only larger populations, but a wider host range as well [30]. Routes of transmission also dictate the prevalence and risk of outbreak in human populations. The prevalence of infection in the primary animal host population, the rate of encounter of these animals with humans and the probability of humans becoming infected upon contact constitute outbreak risks [33]. However, it should be noted that several fungi are not restricted to one mode of transmission [30]. For example, some dermatophytes are highly contagious and can easily jump to a new host by direct contact, but can also survive for extended periods on keratinized fomites to be transmitted indirectly [23,34]. The adaptation of zoophilic dermatophytes to the human host may occur within a rather short time span [35].

4. Are Fungal Pathogens of Close Human Relatives More Likely to Cause Outbreaks in Humans?

Pathogens often coevolve with their hosts; thus, many pathogenic microorganisms are adapted to and infect a limited number of host species [36,37]. Specific ligand–receptor interactions between an infectious agent and its host must occur for a pathogen to access and multiply on an infectable surface; colonize, invade and multiply inside the host; and resist its innate and/or adaptive immune mechanisms. Following this concept, for the successful invasion of a new category of hosts, the pathogen has to re-adapt to some or all of these interactions. For pathogens outside the fungal kingdom, it has been hypothesized that those of non-human primates have a higher probability to cross the species barrier and infect humans, as opposed to those associated with phylogenetically more distant hosts [38]. In support of this, in proportion to the number of species in the same taxon, pathogens of non-human primates contribute more to human infectious diseases than those of non-primate mammals [36,38]. This barrier to transmission of pathogens between species is referred to as the “species barrier”, indicating the host specificity of the agent. In fungi, this is known, e.g., in Pneumocystis [39], where the numerous extant species have restricted host ranges, and the human-associated species, P. jirovecii, has been found to infect humans only [40]. However, this concept of specificity and species barrier is less applicable to fungi, which seem to be less dependent on particular hosts. For instance, Microsporum canis, a pathogen of cats, dogs and horses is also transmissible between humans [37], causing small, self-limiting outbreaks in school children [41,42].
Janzen [43] introduced the concept of “ecological fitting”, which seems to provide a suitable alternative explanation for host shifts in fungi. In the context of host–pathogen interaction, “ecological fitting” is the mechanism whereby the pathogen persists in the novel non-optimal environment of the new host, using existing traits that have evolved elsewhere and in response to a different set of environmental conditions [44,45]. Ecological fitting may occur through two scenarios. First, through similarity in the resources provided by the previous and novel host, referred to as ecological fitting via resource tracking. From a pathogen’s perspective, the new host may actually not be so different from the previous one, as long as essential conditions for infection are the same [36,46]. Here, similarities can be closely linked to the phylogenetic relatedness of the hosts [47]. However, several pathogenic fungi also have the ability to survive and adapt under sub-optimal conditions, e.g., temperature [48]. In the second scenario, fungi have what is known as a broad “sloppy fitness space”, which facilitates new associations between species or simply expands the number of potential hosts: ecological fitting via sloppy fitness space [45]. The main limitation is that for the fungal pathogens to jump to humans, their primary host must also be a mammal, as host shifts from other vertebrates such as birds, amphibians and fish are highly exceptional. Most environmental fungal pathogens of rodents, bats or armadillos have a sufficiently wide fitness space to be able to infect humans [48].

5. Some Examples of Animal-Associated Fungal Infections

In recent years, the epidemiological patterns of some fungal diseases associated with domesticated and wild animals have changed, showing an increased prevalence, death toll or change in populations at risk. Here, we summarize and review new insights and findings of some important animal-associated fungal infections. Using specific examples, we delve into the concepts discussed above: mode of transmission, host shift and classification of causative fungal pathogen in relation to the risk of outbreaks and threat to public health.

5.1. Dermatophytoses

Dermatophytosis, commonly known as ringworm or tinea, occurs worldwide, but currently, a change is being observed in the epidemiology of the disease. The distribution of species causing the disease now varies significantly between countries. This has been attributed to inappropriate treatment, high population density, traveling and migration, among other factors [49,50,51]. With the domestication of animals as pets, new species such as T. erinacei and T. benhamiae have also emerged in humans, causing an increase in zoonotic infections [25,52]. Concerns arise as the elevated cost and lengthy treatment of dermatophytosis frequently leads to a non-adherence to therapy, with an emergence of resistance as a serious consequence [53].
Recently, considerable alarm has been raised due to an ongoing large-scale dermatophytosis outbreak in India, which is spreading to other countries [54]. The disease spreads among humans, typical of anthropophilic causative agents, but manifests a severity of symptoms typical of a zoophilic dermatophyte. The outbreak has been attributed to a novel species, Trichophyton indotineae [55], which shows increased virulence as opposed to the previously widespread T. mentagrophytes and T. interdigitale [54]. Tang et al. [35] have suggested that what is being observed is the geophilic, wild animal-infecting species, T. mentagrophytes, shifting host to domesticated animals and now behaving as an anthropophilic clonal offshoot. The Indian strain is also more frequently resistant to antifungal drugs, which has been attributed to the overuse of common antifungals by the public. Consequently, the disease is hard to control, and occurrence of the dermatophyte is on the rise [35,56].
A case of host shift has been noted earlier in the dermatophyte Trichophyton equinum infecting horses. Kandemir et al. [57] describes Trichophyton tonsurans, which causes tinea capitis in humans as the anthropophilic counterpart of T. equinum. Here, rapid evolution towards anthropophily may have occurred by the clonal emergence of mating types.

5.2. Sporotrichosis

In recent years, zoonotic sporotrichosis has become an emerging public health issue in Latin America and has taken the proportion of an epidemic [58]. In the state of Rio de Janeiro alone, cases have escalated from a few hundred in the late 1990s to more than 10,000 in the year 2017 [59]. Two species are the cause of the ongoing feline epizootic and epidemic: Sporothrix brasiliensis and Sporothrix sckenckii sensu stricto, the former predominating [59].
The emergence of Sporothrix brasiliensis in cats in Brazil has been linked to a lifestyle shift of a saprobic Sporothrix species. The acquired ability of the fungus to survive at the relatively high body temperature of cats may be related to global warming [58,60]. The fungus easily spreads among cats through scratches and bites in fights. Cases in humans occur exclusively by zoonotic transmission. An epidemiological relationship has been observed between the number of infected cats in the urban areas of Brazil and diagnosis in humans [61]. Although cats are the primary vector, Sporothrix brasiliensis also prevails among dogs and rats [62]. As for dermatophytes, zoophilic Sporothrix brasiliensis is more virulent than previously known species. Alarmingly, the fungus is also insensitive to some antifungal treatments [62,63]. The prevalence of the disease keeps increasing in Brazil and is now spreading to adjacent Argentinian states [61].
As opposed to the Brazilian species, Sporothrix sckenckii sensu stricto occurs worldwide. Zoonotic transmission has been reported mainly from cats, but also dogs, squirrels, rats and armadillos. Sporothrix globosa, S. mexicana and S. luriei, also occur in humans but are commonly acquired through the inhalation of conidia rather than animal transmission [62,64,65].

5.3. Histoplasmosis

Approximately 500,000 people suffer from histoplasmosis annually, 100,000 develop disseminated histoplasmosis and 25,000 die from the disease [1]. Histoplasmosis is emerging worldwide. Originally, the disease was endemic in Ohio, Mississippi; St. Lawrence River Valley in America; and in sub-Saharan Africa [66,67], but it now extends to the Caribbean, Southeastern Asia and South and Central America [68]. As the disease is often misdiagnosed (e.g., as tuberculosis or emergomycosis) and notification of infection to the authorities is not mandatory in many countries, its geographical prevalence and distribution may still be underestimated [69,70].
The causative agent of the disease is the dimorphic fungus Histoplasma capsulatum, which was first isolated in Mexico. Recent studies have revealed that H. capsulatum is a species complex rather than a single species. Sepúlveda et al. [71] established a number of sibling species within the H. capsulatum complex on the basis of population genomic data, each with an approximately restricted geographic distribution. The genetic diversity between populations is considerable [72,73], and the fungus comprises at least four distinct genetic groups of differing virulence [71].
Histoplasmosis, once known as the “cave sickness” [74], has been strongly associated with bats. Several species and populations of Chiroptera, belonging to Molossidae, Phyllostomidae, Vespertilionidae and Emballonuridae, have been reported with the disease [75,76]. Histoplasmosis has also been reported in birds, but only sporadically [73]. However, rather than being zoonotic, the causative agent, H. capsulatum, thrives in the feces of bats and birds and in soils enriched with their fecal matter [25,66]. Interestingly, an overlap was found between the geographical occurrence of infected bats and regions of histoplasmosis endemicity [77]. As infected bats travel for long distances and migrate, they spread the pathogen [70,78]. Among mammals, bats are the second most speciose group after rodents; they have a worldwide distribution and live in colonies, which are sometimes found in close proximity to humans. These features make bats a continued source of emerging pathogens [36]. However, encroachment into wildlife habitats related to touristic activities such as bird and bat watching, caving or construction and excavation work should be regarded as the main reasons for the spillover of histoplasmosis in humans [79,80].
A wide range of mammalian hosts including bears, monkeys, apes and several felines have also been reported with H. capsulatum infection [81]. Teixeira et al. [73] found that isolates of H. capsulatum from specific mammalian hosts formed monophyletic clades, suggesting that mammals play a key role in the diversification (e.g., strains) and the mechanism by which the fungus disperses. Other authors have also discussed the significance of animal hosts in the evolution of new pathogenic fungal species [82]. Wide host range is yet another characteristic of an emerging disease [83].
Histoplasmosis is typically contracted by the inhalation of airborne conidia from the environment and usually affects AIDS patients. However, cases have recently been reported in otherwise immunocompetent individuals [68,84,85]. In general, histoplasmosis symptomatology ranges from asymptomatic in immunocompetent patients to fatal in immunocompromised ones [86]. In addition, the severity of the infection also depends on the inoculum size and age of the individual [80], but unexpected cases do occur. In a recent outbreak, members of a film crew suffered from histoplasmosis after working in a vampire bat cave. One of them, a young man in his thirties with no underlying conditions, suffered from acute pulmonary histoplasmosis, as he occasionally removed his mask [87].

5.4. Cryptococcosis

Beyond the tropics and the sub-tropics, cryptococcosis is now recognized as one of the deadliest fungal diseases worldwide [8,88]. Since the first case report in the mid 1980s, the epidemiology of cryptococcosis has evolved [89]. The emerging invasive fungal disease now kills both treated and untreated patients with and without underlying immune defects [89], causing a death toll of over 180,000 annually [20,90]. The course of the disease can be insidious or can cause a range of symptoms. Meningoencephalitis is common in HIV-positive and other immunosuppressed patients and is often caused by Cryptococcus neoformans. Concurrently, C. gattii is increasingly being diagnosed in immunocompetent individuals causing pulmonary infection [91].
In terms of diseases related to and dispersed by animals, Cryptococcus neoformans is of main concern as it typically thrives in bird excreta. The habitat of Cryptococcus gatti comprises of plants, particularly eucalyptus [91]. However, species belonging to both the C. neoformans and C. gattii species complexes shift to an infective yeast form once they go through the respiratory system of mammals. Numerous cases, outbreaks and epidemics of cryptococcosis by the two species complexes have been documented in farmed and companion animals: birds, cattle, horses, cats and dogs, among others [92,93,94]. The risk of human cryptococcosis by these infected animals should not be neglected given that they are part of our daily life and have a high potential to contaminate the environment.
Insightful discoveries and advances have been made in the molecular characterization, diagnosis and treatment of cryptococcosis [89,95,96,97]. However, the scarcity of antifungal treatments to treat mycosis and the emergence of antifungal resistance challenges the goal to curb mortality rates [96].

5.5. Emergomycosis

Emergomycosis, previously known as adiaspiromycosis for the giant cell variant, is caused by members of Emergomyces [98]. This genus is particularly interesting due to the numerous drastic changes that have been made to its classification within just a few years [99]. The previous type species Emmonsia parva has been moved to Blastomyces. Additionally, Emmonsia crescens and E. soli have been reassigned to Emergomyces, although the morphology and size of their invasive stage (a determinant characteristic for delineating dimorphic fungi at a generic level) differ significantly from other members of the genus. Additionally, Emergomyces species show considerable variation in their virulence and clinical manifestations [99,100,101]. Previously, due to the unconventional characteristics of Emergomyces, the identification of species causing emergomycosis was difficult and ambiguous. These were collectively referred to as emmonsia-like species (Emmonsia sp.) in reference to the resemblance in symptoms of the disease (adiaspiromycosis) caused by Emmonsia crescens and Emmonsia parva [99,100]. Recent phylogenetic analysis separated them into five distinct species belonging to Emergomyces (E. africanus, E. canadensis, E. europaeus, E. orientalis and E. pasteurianus).
Currently, seven species are known to cause emergomycosis. These include exclusive human pathogens as well as pathogens common to both humans and other animals. Emergomyces crescens is normally associated with small burrowing mammals, particularly Cricetidae and Muridae rodents [48,102]. Cases in other rodents and humans occur occasionally [103]. The disease has thus been considered potentially zoonotic with small rodents and their predators as vectors; however, conclusive evidence is yet to be found. Jiang et al. [48,99] suggested that zoonotic infection by E. crescens remains highly unlikely, as a higher frequency of infection by the fungus appears in hosts with body temperatures relatively lower (35.0–37.5 °C) than that of humans. Emergomyces africanus with increased prevalence, causing hundreds of deaths in HIV patients yearly, is exclusively found in humans. Yet emergomycosis remains of particular interest when dealing with animal-associated fungal diseases in humans, as it strongly resembles histoplasmosis in its clinical presentations and diagnostic test results. Anthropophilic Emergomyces species, such as E. africanus, and Histoplasma capsulatum proliferate by forming thin-walled, budding yeast and yeast-like cells, leading to disseminated infection. Dissemination commonly involves the spleen, liver, gastrointestinal tract and bone marrow [104,105]. When the infective agent is sampled and cultured, swollen conidiophores and florets of conidia form fluffy whitish-yellow mycelium in both anthropophilic Emergomyces and Histoplasma capsulatum [99]. However, the mycelial form varies considerably, and if successfully cultured, it can be used as a distinguishing characteristic [44,99]. Ultimately, molecular methods provide a more accurate means for identification [39,106].

5.6. Talaromycosis

Talaromyces marneffei (previously known as Penicillium marneffei) infects around 50,000 HIV positive patients every year in endemic regions [18]. However, in the last decade, a change in the epidemiology of Talaromyces marneffei has been observed. The fungus once considered exclusively AIDS-related now shows association with other types of impairment of cellular immunity such as disorders related to mutation of the STAT-1 gene [107,108]. In Southern China and East India, immunocompetent individuals also seem to be involved [85,109,110,111].
Talaromycosis is described as a soft-tissue infection, but recently, Li et al. [112] stated the radiological findings of bone involvement in non-HIV talaromycosis patients, mainly osteolytic bone destruction in flat bones. Concerns arise as the clinical manifestations of non-HIV talaromycosis develop rapidly, are non-specific and occur concurrently with other opportunistic fungal infections, often leading to misdiagnosis [110,112]. Surprisingly, disease mortality was found to be higher in non-HIV patients than in HIV-positive patients [113].
A newly reported case in a patient who had no recent contact with any known source or reservoir of infection [110] has brought back uncertainties around the ecology and transmission of Talaromyces marneffei. The fungus comprises the sole dimorphic species of Talaromyces [114]. Little is known about the causative agent of talaromycosis. Its natural environmental niche is still debated, and the mechanism through which it invades the host is poorly understood [115]. Infection is presumed to occur through inhalation of conidia from the environment [116]. Zoonotic transmission has also been speculated as strains infecting bamboo rats and humans are genetically similar [117]. A case of disseminated talaromycosis has also been reported in a male who had consumed bamboo rat meat [109]. However, further evidence is needed to confirm the hypothesis of direct transmission from rodents to humans. Since the first isolation of the fungus from the liver of bamboo rats, subsequent studies uncovered the natural occurrence of the fungus in plant materials and soil associated and non-associated with the rodent [14,15,16,17,115].

6. Conclusions

Fungal diseases typically associated with animals continue to emerge in humans mainly due to human modern activities. With increased movement and development along with environmental changes, emerging fungal infections are on the rise and require close surveillance. The emergence of animal-associated diseases in humans is noted as a result of either an increase in the number of cases or as host switch of a known species. In all cases, assessing the risk that these fungi pose to public health may be challenging, as it requires interdisciplinary collaboration. Infections of humans and domestic animals have been studied thoroughly, but knowledge on wildlife habitats is fragmented. Tackling this gap requires collaborative research among many fields, including taxonomy, ecology and epidemiology. The basis of understanding and forecasting epidemics is to trace the source of the disease. Wildlife should be given close attention, yet it should not be spuriously considered as the source of all threatening diseases. If emerging diseases can be predicted early, then preventive methods (e.g., novel pharmaceutical agents) or other methods can be developed in a timely manner [1,3,7]. Though this review is centered on humans and public health, successfully tackling emerging fungal diseases will require a One Health approach, whereby humans, other animals and the environment are considered.

Author Contributions

Conceptualization, J.E.C. and S.d.H.; writing—original draft preparation, J.E.C.; writing—review and editing, J.E.C., S.d.H., E.G. and K.D.H.; funding acquisition, J.E.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by the Mushroom Research Foundation and Mae Fah Luang University.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank Mae Fah Luang University, the Centre of Excellence in Fungal Research and the Mushroom Research Foundation.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Bongomin, F.; Gago, S.; Oladele, R.; Denning, D. Global and multi-national prevalence of fungal diseases—Estimate precision. J. Fungi 2017, 3, 57. [Google Scholar] [CrossRef]
  2. Brown, G.D.; Denning, D.W.; Gow, N.A.R.; Levitz, S.M.; Netea, M.G.; White, T.C. Hidden killers: Human fungal infections. Sci. Transl. Med. 2012, 4, 1–9. [Google Scholar] [CrossRef] [Green Version]
  3. Hyde, K.D.; Al-Hatmi, A.M.S.; Andersen, B.; Boekhout, T.; Buzina, W.; Dawson, T.L.; Eastwood, D.C.; Jones, E.B.G.; de Hoog, S.; Kang, Y.; et al. The world’s ten most feared fungi. Fungal Divers. 2018, 93, 161–194. [Google Scholar] [CrossRef]
  4. Friedman, D.Z.P.; Schwartz, I.S. Emerging fungal infections: New patients, new patterns, and new pathogens. J. Fungi 2019, 5, 67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Siscar-Lewin, S.; Hube, B.; Brunke, S. Emergence and evolution of virulence in human pathogenic fungi. Trends Microbiol. 2022, in press. [Google Scholar] [CrossRef]
  6. Morens, D.M.; Fauci, A.S. Emerging infectious diseases: Threats to human health and global stability. PLoS Pathog. 2013, 9, e1003467. [Google Scholar] [CrossRef] [Green Version]
  7. Rodrigues, M.L.; Nosanchuk, J.D. Fungal diseases as neglected pathogens: A wake-up call to public health officials. PLoS Negl. Trop. Dis. 2020, 14, e0007964. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Fisher, M.C.; Gurr, S.J.; Cuomo, C.A.; Blehert, D.S.; Jin, H.; Stukenbrock, E.H.; Stajich, J.E.; Kahmann, R.; Boone, C.; Denning, D.W.; et al. Threats Posed by the Fungal Kingdom to Humans, Wildlife, and Agriculture Downloaded from. Philos. Trans. R. Soc. B Biol. Sci. 2020, 371, 20160332. [Google Scholar] [CrossRef] [Green Version]
  9. Van Rhijn, N.; Bromley, M. The Consequences of Our Changing Environment on Life Threatening and Debilitating Fungal Diseases in Humans. J. Fungi 2021, 7, 367. [Google Scholar] [CrossRef] [PubMed]
  10. Nnadi, N.E.; Carter, D.A. Climate change and the emergence of fungal pathogens. PLoS Pathog. 2021, 17, e1009503. [Google Scholar] [CrossRef]
  11. Mesquita, J.R. Emerging and re-emerging diseases: Novel challenges in today’s world or more of the same? Animals 2021, 11, 2382. [Google Scholar] [CrossRef]
  12. Willinger, B. Emerging fungi and diagnosis of fungal infections: Current knowledge and new developments. J. Fungi 2021, 7, 316. [Google Scholar] [CrossRef] [PubMed]
  13. Roilides, E. Emerging fungi causing human infection: New or better identified? Clin. Microbiol. Infect. 2016, 22, 660–661. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  14. Ajello, L.; Padhye, A.A.; Sukroongreung, S.; Nilakul, C.H.; Tantimavanic, S. Occurrence of Penicillium marneffei infections among wild bamboo rats in Thailand. Mycopathologia 1995, 131, 1–8. [Google Scholar] [CrossRef] [PubMed]
  15. Chariyalertsak, S.; Vanittanakom, P.; Nelson, K.E.; Sirisanthana, T.; Vanittanakom, N. Rhizomys sumatrensis and Cannomys badius, new natural animal hosts of Penicillium marneffei. J. Med. Vet. Mycol. 1996, 34, 105. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  16. Deng, Z.; Yun, M.; Ajello, L. Human penicilliosis marneffei and its relation to the bamboo rat (Rhizomys pruinosus). J. Med. Vet. Mycol. 1986, 24, 383–389. [Google Scholar] [CrossRef]
  17. Gugnani, H.; Fisher, M.C.; Paliwal-Johsi, A.; Vanittanakom, N.; Singh, I.; Yadav, P.S. Role of Cannomys badius as a natural animal host of Penicillium marneffei in India. J. Clin. Microbiol. 2004, 42, 5070–5075. [Google Scholar] [CrossRef] [Green Version]
  18. Jiang, J.; Meng, S.; Huang, S.; Ruan, Y.; Lu, X.; Li, J.Z.; Wu, N.; Huang, J.; Xie, Z.; Liang, B.; et al. Effects of Talaromyces marneffei infection on mortality of HIV/AIDS patients in southern China: A retrospective cohort study. Clin. Microbiol. Infect. 2019, 25, 233–241. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  19. Chomel, B.B.; Belotto, A.; Meslin, F.X. Wildlife, exotic pets, and emerging zoonoses. Emerg. Infect. Dis. 2007, 13, 6–11. [Google Scholar] [CrossRef]
  20. Fisher, M.C. Epidemiological Definitions, Terminology and Classifications with Reference to Fungal Infections of Animals. In Emerging and Epizootic Fungal Infections in Animals; Springer International Publishing: Cham, Switzerland, 2018; pp. 17–27. [Google Scholar]
  21. Schaefer, H.E. Introduction into pathology of ocular zoonoses. Int. J. Med. Sci. 2009, 6, 120–122. [Google Scholar] [CrossRef] [Green Version]
  22. De Hoog, G.S.; Ahmed, S.A.; Danesi, P.; Guillot, J.; Gräser, Y. Distribution of Pathogens and Outbreak Fungi in the Fungal Kingdom. In Emerging and Epizootic Fungal Infections in Animals; Springer International Publishing: Cham, Switzerland, 2018; pp. 3–16. [Google Scholar]
  23. Hubálek, Z.; Rudolf, I. Microbial Zoonoses and Sapronoses; Springer: Dordrecht, The Netherlands, 2010. [Google Scholar]
  24. Bauerfeind, R.; Von Graevenitz, A.; Kimmig, P.; Schiefer, H.G.; Schwarz, T.; Slenczka, W.; Zahner, H. Infectious Diseases Transmissible from Animals to Humans; John Wiley & Sons: Washington, DC, USA, 2020. [Google Scholar]
  25. Seyedmousavi, S.; de Hoog, G.S.G.S.; Guillot, J.; Verweij, P.E. Emerging and Epizootic Fungal Infections in Animals; Springer: Cham, Switzerland, 2018. [Google Scholar]
  26. Kuris, A.M.; Lafferty, K.D.; Sokolow, S.H. Sapronosis: A distinctive type of infectious agent. Trends Parasitol. 2014, 30, 386–393. [Google Scholar] [CrossRef]
  27. Gauthier, G.M. Dimorphism in fungal pathogens of mammals, plants, and insects. PLoS Pathog. 2015, 11, e1004608. [Google Scholar] [CrossRef]
  28. Da Silva, J.A.; Scofield, A.; Barros, F.D.N.; de Farias, D.M.; Riet-Correa, G.; Bezerra Junior, P.S.; Santos, T.F.S.; Tavares, G.S.F.; Trevelin, L.C.; da Paz, G.S.; et al. Molecular detection of Histoplasma capsulatum in bats of the Amazon biome in Pará state, Brazil. Transbound. Emerg. Dis. 2021, 68, 758–766. [Google Scholar] [CrossRef]
  29. De Hoog, G.; Guarro, J.; Gené, J.; Ahmed, S.; Al-Hatmi, A.; Figueras, M.; Vitale, R. Atlas of Clinical Fungi. Available online: https://www.clinicalfungi.org/page/Educational (accessed on 9 May 2022).
  30. Woolhouse, M.E.J. Population biology of emerging and re-emerging pathogens. Trends Microbiol. 2002, 10, s3–s7. [Google Scholar] [CrossRef]
  31. Blackburn, J.K.; Ganz, H.H.; Ponciano, J.M.; Turner, W.C.; Ryan, S.J.; Kamath, P.; Cizauskas, C.; Kausrud, K.; Holt, R.D.; Stenseth, N.C.; et al. Modeling R 0 for pathogens with environmental transmission: Animal movements, pathogen populations, and local infectious zones. Int. J. Environ. Res. Public Health 2019, 16, 954. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Lange, M.; Kramer-Schadt, S.; Thulke, H.H. Relevance of indirect transmission for wildlife disease surveillance. Front. Vet. Sci. 2016, 3, 110. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Viana, M.; Mancy, R.; Biek, R.; Cleaveland, S.; Cross, P.C.; Lloyd-Smith, J.O.; Haydon, D.T. Assembling evidence for identifying reservoirs of infection. Trends Ecol. Evol. 2014, 29, 270–279. [Google Scholar] [CrossRef] [Green Version]
  34. Spickler, A. The Centre for Food Security & Public Health. Available online: www.cfsph.iastate.edu (accessed on 28 May 2020).
  35. Tang, C.; Kong, X.; Ahmed, S.A.; Thakur, R.; Chowdhary, A.; Nenoff, P.; Uhrlass, S.; Verma, S.B.; Meis, J.F.; Kandemir, H.; et al. Taxonomy of the Trichophyton mentagrophytes/T. interdigitale species complex harboring the highly virulent, multiresistant genotype T. indotineae. Mycopathologia 2021, 186, 315–326. [Google Scholar] [CrossRef] [PubMed]
  36. Wong, S.; Lau, S.; Woo, P.; Yuen, K.Y. Bats as a continuing source of emerging infections in humans. Rev. Med. Virol. 2007, 17, 67–91. [Google Scholar] [CrossRef]
  37. Sansonetti, P.; Tubiana, M.; Binet, J.L.; Nordmann, R.; Nezelof, C. Peut-on concrètement définir la notion de barrière d’espèce à la diffusion des pathogènes? Bull. Acad. Natl. Med. 2006, 190, 611–623. [Google Scholar] [CrossRef]
  38. Wolfe, N.D.; Dunavan, C.P.; Diamond, J. Origins of Major Human Infectious Diseases. In Improving Food Safety through a One Health Approach: Workshop Summary; National Academies Press: Washington, DC, USA, 2012. [Google Scholar]
  39. Danesi, P.; Ravagnan, S.; Johnson, L.R.; Furlanello, T.; Milani, A.; Martin, P.; Boyd, S.; Best, M.; Galgut, B.; Irwin, P.; et al. Molecular diagnosis of Pneumocystis pneumonia in dogs. Med. Mycol. 2017, 55, 828–842. [Google Scholar] [CrossRef]
  40. Calderón, E.J. Epidemiology of Pneumocystis infection in Human. J. Mycol. Med. 2009, 19, 270–275. [Google Scholar] [CrossRef]
  41. Grills, C.E.; Bryan, P.L.; O’Moore, E.; Venning, V.A. Microsporum canis: Report of a primary school outbreak. Australas. J. Dermatol. 2007, 48, 88–90. [Google Scholar] [CrossRef] [PubMed]
  42. Yu, J.; Wan, Z.; Chen, W.; Wang, W.; Li, R. Molecular typing study of the Microsporum canis strains isolated from an outbreak of tinea capitis in a school. Mycopathologia 2004, 157, 37–41. [Google Scholar] [CrossRef] [PubMed]
  43. Janzen, D.H. On Ecological Fitting. Oikos 1985, 45, 308–310. [Google Scholar] [CrossRef] [Green Version]
  44. Araujo, S.B.L.; Braga, M.P.; Brooks, D.R.; Agosta, S.J.; Hoberg, E.P.; von Hartenthal, F.W.; Boeger, W.A. Understanding host-switching by ecological fitting. PLoS ONE 2015, 10, e0139225. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Agosta, S.J.; Klemens, J.A. Ecological fitting by phenotypically flexible genotypes: Implications for species associations, community assembly and evolution. Ecol. Lett. 2008, 11, 1123–1134. [Google Scholar] [CrossRef] [PubMed]
  46. Rohde, K. The Balance of Nature and Human Impact; Cambridge University Press: Cambridge, UK, 2013. [Google Scholar]
  47. Agosta, S.; Janz, N.; Brooks, D. How specialists can be generalists: Resolving the ‘parasite paradox’ and implications for emerging infectious disease. Zoologia 2010, 27, 151–162. [Google Scholar] [CrossRef] [Green Version]
  48. Jiang, Y.; Dukik, K.; Muñoz, J.F.; Sigler, L.; Schwartz, I.S.; Govender, N.P.; Kenyon, C.; Feng, P.; van den Ende, B.G.; Stielow, J.B.; et al. Phylogeny, ecology and taxonomy of systemic pathogens and their relatives in Ajellomycetaceae (Onygenales): Blastomyces, Emergomyces, Emmonsia, Emmonsiellopsis. Fungal Divers. 2018, 90, 245–291. [Google Scholar] [CrossRef] [Green Version]
  49. Waśkiel-Burnat, A.; Rakowska, A.; Sikora, M.; Ciechanowicz, P.; Olszewska, M.; Rudnicka, L. Trichoscopy of tinea capitis: A systematic review. Dermatol. Ther. 2020, 10, 43–52. [Google Scholar] [CrossRef] [Green Version]
  50. Ebrahimi, M.; Zarrinfar, H.; Naseri, A.; Najafzadeh, M.J.; Fata, A.; Parian, M.; Khorsand, I.; Babič, M.N. Epidemiology of dermatophytosis in northeastern Iran; A subtropical region. Curr. Med. Mycol. 2019, 5, 16. [Google Scholar] [CrossRef]
  51. Rosalie, S.; Lize, C.; Laurence, S.; Rajae, D.; Caroline, A.; Katrien, L.; Marie-Pierre, H. Epidemiology of dermatophytes in Belgium: A 5 years’ survey. Mycopathologia 2021, 186, 399–409. [Google Scholar] [CrossRef]
  52. Hsieh, C.W.; Sun, P.L.; Wu, Y.H. Trichophyton erinacei infection from a hedgehog: A case report from Taiwan. Mycopathologia 2010, 170, 417–421. [Google Scholar] [CrossRef]
  53. Ho, F.K.H.; Delgado-Charro, M.B.; Bolhuis, A. Evaluation of an explanted porcine skin model to investigate infection with the dermatophyte Trichophyton rubrum. Mycopathologia 2020, 185, 233–243. [Google Scholar] [CrossRef] [PubMed]
  54. Nenoff, P.; Verma, S.B.; Vasani, R.; Burmester, A.; Hipler, U.C.; Wittig, F.; Krüger, C.; Nenoff, K.; Wiegand, C.; Saraswat, A.; et al. The current Indian epidemic of superficial dermatophytosis due to Trichophyton mentagrophytes—A molecular study. Mycoses 2019, 62, 336–356. [Google Scholar] [CrossRef] [PubMed]
  55. Kano, R.; Kimura, U.; Kakurai, M.; Hiruma, J.; Kamata, H. Trichophyton indotineae sp. nov.: A new highly terbinafine-resistant anthropophilic dermatophyte species. Mycopathologia 2020, 185, 947–958. [Google Scholar] [CrossRef] [PubMed]
  56. Singh, A.; Masih, A.; Monroy-Nieto, J.; Singh, P.K.; Bowers, J.; Travis, J.; Khurana, A.; Engelthaler, D.M.; Meis, J.F.; Chowdhary, A. A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance pr. Fungal Genet. Biol. 2019, 133, 103266. [Google Scholar] [CrossRef]
  57. Kandemir, H.; Dukik, K.; Hagen, F.; Ilkit, M.; Gräser, Y.; de Hoog, G.S. Polyphasic discrimination of Trichophyton tonsurans and T. equinum from humans and horses. Mycopathologia 2020, 185, 113–122. [Google Scholar] [CrossRef] [PubMed]
  58. Etchecopaz, A.; Toscanini, M.A.; Gisbert, A.; Mas, J.; Scarpa, M.; Iovannitti, C.A.; Bendezú, K.; Nusblat, A.D.; Iachini, R.; Cuestas, M.L. Sporothrix brasiliensis: A Review of an Emerging South American Fungal Pathogen, Its Related Disease, Presentation and Spread in Argentina. J. Fungi 2021, 7, 170. [Google Scholar] [CrossRef] [PubMed]
  59. Bongomin, F. GAFFI Factsheet Sporotrichosis. Available online: https://www.gaffi.org/wp-content/uploads/Sporotrichosis-GAFFI-Fact-sheet-v4-.pdf (accessed on 9 May 2022).
  60. Inokuma, D.; Shibaki, A.; Shimizu, H. Two cases of cutaneous sporotrichosis in continental/microthermal climate zone: Global warming alert? Clin. Exp. Dermatol. 2010, 35, 668–669. [Google Scholar] [CrossRef]
  61. De Oliveira Bento, A.; de Sena Costa, A.S.; Lima, S.L.; Do Monte Alves, M.; de Azevedo Melo, A.S.; Rodrigues, A.M.; da Silva-Rocha, W.P.; Milan, E.P.; Chaves, G.M. The spread of cat-transmitted sporotrichosis due to Sporothrix brasiliensis in Brazil towards the Northeast region. PLoS Negl. Trop. Dis. 2021, 15, e0009693. [Google Scholar] [CrossRef]
  62. Rossow, J.A.; Queiroz-Telles, F.; Caceres, D.H.; Beer, K.D.; Jackson, B.R.; Pereira, J.G.; Gremião, I.D.F.; Pereira, S.A. A One Health Approach to Combatting Sporothrix brasiliensis: Narrative Review of an Emerging Zoonotic Fungal Pathogen in South America. J. Fungi 2020, 6, 247. [Google Scholar] [CrossRef]
  63. Gremião, I.D.F.; Miranda, L.H.M.; Reis, E.G.; Rodrigues, A.M.; Pereira, S.A. Zoonotic Epidemic of Sporotrichosis: Cat to Human Transmission. PLoS Pathog. 2017, 13, e1006077. [Google Scholar] [CrossRef]
  64. De Carolis, E.; Posteraro, B.; Sanguinetti, M. Old and New Insights into Sporothrix schenckii Complex Biology and Identification. Pathogens 2022, 11, 297. [Google Scholar] [CrossRef]
  65. Toriello, C.; Brunner-Mendoza, C.; Ruiz-Baca, E.; Duarte-Escalante, E.; Pérez-Mejía, A.; del Rocío Reyes-Montes, M. Sporotrichosis in Mexico. Braz. J. Microbiol. 2021, 52, 49–62. [Google Scholar] [CrossRef] [PubMed]
  66. Antinori, S. Histoplasma capsulatum: More widespread than previously thought. Am. J. Trop. Med. Hyg. 2014, 90, 982–983. [Google Scholar] [CrossRef] [Green Version]
  67. Bahr, N.C.; Antinori, S.; Wheat, L.J.; Sarosi, G.A. Histoplasmosis infections worldwide: Thinking outside of the Ohio River Valley. Curr. Trop. Med. Rep. 2015, 2, 70–80. [Google Scholar] [CrossRef] [Green Version]
  68. Bongomin, F.; Kwizera, R.; Denning, D.W. Getting histoplasmosis on the map of international recommendations for patients with advanced HIV disease. J. Fungi 2019, 5, 80. [Google Scholar] [CrossRef] [Green Version]
  69. Adenis, A.A.; Valdes, A.; Cropet, C.; McCotter, O.Z.; Derado, G.; Couppie, P.; Chiller, T.; Nacher, M. Burden of HIV-associated histoplasmosis compared with tuberculosis in Latin America: A modelling study. Lancet Infect. Dis. 2018, 18, 1150–1159. [Google Scholar] [CrossRef]
  70. De Abreu Almeida, M.; Almeida-Silva, F.; Guimarães, A.J.; Almeida-Paes, R.; Zancopé-Oliveira, R.M. The occurrence of histoplasmosis in Brazil: A systematic review. Int. J. Infect. Dis. 2019, 86, 147–156. [Google Scholar] [CrossRef] [Green Version]
  71. Sepúlveda, V.E.; Márquez, R.; Turissini, D.A.; Goldman, W.E.; Matute, D.R. Genome sequences reveal cryptic speciation in the human pathogen Histoplasma capsulatum. MBio 2017, 8, e01339-17. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Rodrigues, A.M.; Beale, M.A.; Hagen, F.; Fisher, M.C.; Terra, P.P.D.; de Hoog, S.; Brilhante, R.S.N.; de Aguiar Cordeiro, R.; de Souza, C.M.C.B.; Rocha, M.F.G.; et al. The global epidemiology of emerging Histoplasma species in recent years. Stud. Mycol. 2020, 97, 100095. [Google Scholar] [CrossRef]
  73. Teixeira, M.D.M.; Patané, J.S.; Taylor, M.L.; Gómez, B.L.; Theodoro, R.C.; de Hoog, S.; Engelthaler, D.M.; Zancopé-Oliveira, R.M.; Felipe, M.S.; Barker, B.M. Worldwide phylogenetic distributions and population dynamics of the genus Histoplasma. PLoS Negl. Trop. Dis. 2016, 10, e0004732. [Google Scholar] [CrossRef] [Green Version]
  74. Emmons, C.W. Association of bats with histoplasmosis. Public Health Rep. 1958, 73, 590–595. [Google Scholar] [CrossRef]
  75. Dias, M.; Oliveira, R.; Giudice, M.; Netto, H.; Jordão, L.; Grigorio, L.; Rosa, A.; Amorim, J.; Nosanchuk, J.; Travassos, L.; et al. Isolation of Histoplasma capsulatum from bats in the urban area of Saõ Paulo State, Brazil. Epidemiol. Infect. 2019, 139, 1642–1644. [Google Scholar] [CrossRef]
  76. Dos Santos, B.; Langoni, H.; da Silva, R.C.; Menozzi, B.D.; Bosco, S.D.M.G.; Paiz, L.M.; Augusto, L.C.R.; Richini-Pereira, V.B. Molecular detection of Histoplasma capsulatum in insectivorous and frugivorous bats in Southeastern Brazil. Med. Mycol. 2018, 56, 937–940. [Google Scholar] [CrossRef]
  77. Tesh, R.B.; Arata, A.A.; Schneidau, J.D. Histoplasmosis in Colombian bats, with a consideration of some of the factors influencing the prevalence of natural infection in chiroptera. Am. J. Trop. Med. Hyg. 1968, 17, 102–106. [Google Scholar] [CrossRef] [PubMed]
  78. Guerra, B.T.; Almeida-Silva, F.; Almeida-Paes, R.; Basso, R.P.; Bernardes, J.P.R.A.; Almeida, M.A.; Damasceno, L.S.; Xavier, M.O.; Wanke, B.; Zancopé-Oliveira, R.M.; et al. Histoplasmosis outbreaks in Brazil: Lessons to learn about preventing exposure. Mycopathologia 2020, 185, 1–12. [Google Scholar] [CrossRef] [PubMed]
  79. Banerjee, S.; Denning, D.; Chakrabarti, A. One Health aspects & priority roadmap for fungal diseases: A mini-review. Indian J. Med. Res. 2021, 153, 311. [Google Scholar] [CrossRef] [PubMed]
  80. Diaz, J.H. Environmental and wilderness-related risk factors for histoplasmosis: More than bats in caves. Wilderness Environ. Med. 2018, 29, 531–540. [Google Scholar] [CrossRef] [Green Version]
  81. Ahasan, S.A.; Chowdhury, E.H.; Khan, M.A.H.; Parvin, R.; Azam, S.U.; Begum, J.A.; Mohiuddin, G.; Uddin, J.; Rahman, M.M.; Rahman, M.A. Histopathological identification of histoplasmosis in animals at Dhaka zoo. Bangl. J. Vet. Med. 2013, 11, 177–181. [Google Scholar] [CrossRef] [Green Version]
  82. Bagagli, E.; Theodoro, R.; Bosco, S.; McEwen, J. Paracoccidioides brasiliensis: Phylogenetic and ecological aspects. Mycopathologia 2008, 165, 197–207. [Google Scholar] [CrossRef] [Green Version]
  83. Woolhouse, M.E.J.; Gowtage-Sequeria, S. Host range and emerging and reemerging pathogens. Emerg. Infect. Dis. 2005, 11, 1842–1847. [Google Scholar] [CrossRef]
  84. Samaddar, A.; Sharma, A.; Ph, A.K.; Srivastava, S.; Shrimali, T.; Gopalakrishnan, M.; Bohra, G.K. Disseminated histoplasmosis in immunocompetent patients from an arid zone in Western India: A case series. Med. Mycol. Case Rep. 2019, 25, 49–52. [Google Scholar] [CrossRef] [PubMed]
  85. Dang, Y.; Jiang, L.; Zhang, J.; Pan, B.; Zhu, G.; Zhu, F.; Guo, Z.; Wang, B.; Zhang, G.; Weng, Y.; et al. Disseminated histoplasmosis in an immunocompetent individual diagnosed with gastrointestinal endoscopy: A case report. BMC Infect. Dis. 2019, 19, 992. [Google Scholar] [CrossRef]
  86. Benedict, K.; Beer, K.D.; Jackson, B.R. Histoplasmosis-related healthcare use, diagnosis, and treatment in a commercially insured population, United States. Clin. Infect. Dis. 2020, 70, 1003–1010. [Google Scholar] [CrossRef] [Green Version]
  87. Muhi, S.; Crowe, A.; Daffy, J. Acute pulmonary histoplasmosis outbreak in a documentary film crew travelling from Guatemala to Australia. Trop. Med. Infect. Dis. 2019, 4, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  88. Santín, M.; Calero-Bernal, R.; Carmena, D.; Mateo, M.; Balseiro, A.; Barral, M.; Lima Barbero, J.F.; Habela, M.Á. Molecular Characterization of Enterocytozoon bieneusi in Wild Carnivores in Spain. J. Eukaryot. Microbiol. 2018, 65, 468–474. [Google Scholar] [CrossRef]
  89. Perfect, J.R.; Bicanic, T. Cryptococcosis diagnosis and treatment: What do we know now. Fungal Genet. Biol. 2015, 78, 49–54. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  90. Zavala, S.; Baddley, J.W. Cryptococcosis. Semin. Respir. Crit. Care Med. 2020, 41, 69–79. [Google Scholar] [CrossRef]
  91. Gushiken, A.C.; Saharia, K.K.; Baddley, J.W. Cryptococcosis. Infect. Dis. Clin. N. Am. 2021, 35, 493–514. [Google Scholar] [CrossRef]
  92. Refai, M.; El-Hariri, M.; Alarousy, R. Cryptococcosis in Animals and Birds: A Review. Eur. J. Acad. Essays 2017, 4, 202–223. [Google Scholar]
  93. Siqueira, N.P.; Favalessa, O.C.; Maruyama, F.H.; Dutra, V.; Nakazato, L.; Hagen, F.; Hahn, R.C. Domestic Birds as Source of Cryptococcus deuterogattii (AFLP6/VGII): Potential Risk for Cryptococcosis. Mycopathologia 2022, 187, 103–111. [Google Scholar] [CrossRef]
  94. Firacative, C.; Meyer, W.; Castañeda, E. Cryptococcus neoformans and Cryptococcus gattii Species Complexes in Latin America: A Map of Molecular Types, Genotypic Diversity, and Antifungal Susceptibility as Reported by the Latin American Cryptococcal Study Group. J. Fungi 2021, 7, 282. [Google Scholar] [CrossRef] [PubMed]
  95. Cuomo, C.A.; Rhodes, J.; Desjardins, C.A. Advances in cryptococcus genomics: Insights into the evolution of pathogenesis. Mem. Inst. Oswaldo Cruz 2018, 113, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  96. Firacative, C.; Trilles, L.; Meyer, W. Recent advances in cryptococcus and cryptococcosis. Microorganisms 2022, 10, 13. [Google Scholar] [CrossRef]
  97. Hsiao, P.J.; Cheng, H.; Kao, Y.H.; Wang, Y.H.; Chiu, C.C.; Chiang, W.F.; Kuo, C.C.; Chuu, C.P.; Wu, K.A. Comparison of laboratory diagnosis, clinical manifestation, and management of pulmonary cryptococcosis: Report of the clinical scenario and literature review. Clin. Chim. Acta 2022, 524, 78–83. [Google Scholar] [CrossRef] [PubMed]
  98. Gnat, S.; Łagowski, D.; Nowakiewicz, A.; Dyla, M. A global view on fungal infections in humans and animals: Infections caused by dimorphic fungi and dermatophytoses. J. Appl. Microbiol. 2021, 131, 2688–2704. [Google Scholar] [CrossRef] [PubMed]
  99. Jiang, Y.; Tsui, C.K.M.; Ahmed, S.A.; Hagen, F.; Shang, Z.; Gerrits van den Ende, A.H.G.; Verweij, P.E.; Lu, H.; de Hoog, G.S. Intraspecific diversity and taxonomy of Emmonsia crescens. Mycopathologia 2020, 185, 613–627. [Google Scholar] [CrossRef] [PubMed]
  100. Schwartz, I.S.; Kenyon, C.; Feng, P.; Govender, N.P.; Dukik, K.; Sigler, L.; Jiang, Y.; Stielow, J.B.; Muñoz, J.F.; Cuomo, C.A.; et al. 50 years of Emmonsia disease in humans: The dramatic emergence of a cluster of novel fungal pathogens. PLoS Pathog. 2015, 11, e1005198. [Google Scholar] [CrossRef] [Green Version]
  101. Govender, N.P.; Grayson, W. Emergomycosis (Emergomyces africanus) in advanced HIV disease. Dermatopathology 2019, 6, 63–69. [Google Scholar] [CrossRef] [PubMed]
  102. Borman, A.; Jiang, Y.; Dukik, K.; Sigler, L. Adiaspiromycosis and Diseases Caused by Related Fungi in Ajellomycetaceae. In Emerging and Epizootic Fungal Infections in Animals; Springer International Publishing: Cham, Switzerland, 2018; pp. 147–158. [Google Scholar]
  103. Koneru, H.; Penupolu, S. Pulmonary adiaspiromycosis: An emerging fungal infection. Chest 2017, 152, A162. [Google Scholar] [CrossRef]
  104. Azar, M.M.; Loyd, J.L.; Relich, R.F.; Wheat, L.J.; Hage, C.A. Current concepts in the epidemiology, diagnosis, and management of histoplasmosis syndromes. Semin. Respir. Crit. Care Med. 2020, 41, 13–30. [Google Scholar] [CrossRef]
  105. Moodley, A.; Mosam, A.; Govender, N.P.; Mahabeer, Y.; Chateau, A.V. Emergomyces africanus: The mimicking fungus. Dermatopathology 2019, 6, 157–162. [Google Scholar] [CrossRef] [PubMed]
  106. Schwartz, I.S.; Govender, N.P.; Sigler, L.; Jiang, Y.; Maphanga, T.G.; Toplis, B.; Botha, A.; Dukik, K.; Claire Hoving, J.; Muñoz, J.F.; et al. Emergomyces: The global rise of new dimorphic fungal pathogens. PLoS Pathog. 2019, 15, e1007977. [Google Scholar] [CrossRef] [Green Version]
  107. Guo, J.; Ning, X.Q.; Ding, J.Y.; Zheng, Y.Q.; Shi, N.N.; Wu, F.Y.; Lin, Y.K.; Shih, H.P.; Ting, H.T.; Liang, G.; et al. Anti-IFN-γ autoantibodies underlie disseminated Talaromyces marneffei infections. J. Exp. Med. 2020, 217, e20190502. [Google Scholar] [CrossRef] [PubMed]
  108. Chan, J.F.; Lau, S.K.; Yuen, K.-Y.; Woo, P.C. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg. Microbes Infect. 2016, 5, 1–9. [Google Scholar] [CrossRef]
  109. Qiu, Y.; Lu, D.C.; Zhang, J.; Zhong, X.; Liu, G.; Li, B. Treatment of disseminated Talaromyces marneffei with tracheal infection: Two case reports. Mycopathologia 2015, 180, 245–249. [Google Scholar] [CrossRef] [PubMed]
  110. He, L.; Mei, X.; Lu, S.; Ma, J.; Hu, Y.; Mo, D.; Chen, X.; Fan, R.; Xi, L.; Xie, T. Talaromyces marneffei infection in non–HIV-infected patients in mainland China. Mycoses 2021, 64, 1170–1176. [Google Scholar] [CrossRef] [PubMed]
  111. Wang, P.; Chen, Y.; Xu, H.; Ding, L.; Wu, Z.; Xu, Z.; Wang, K. Acute disseminated Talaromyces marneffei in an immunocompetent patient. Mycopathologia 2017, 182, 751–754. [Google Scholar] [CrossRef]
  112. Li, X.; Hu, W.; Wan, Q.; Lei, Q.; Sun, C.; Hou, Z.; Shrestha, N. Non-HIV talaromycosis: Radiological and clinical analysis. Medicine 2020, 99, e19185. [Google Scholar] [CrossRef]
  113. Kawila, R.; Chaiwarith, R.; Supparatpinyo, K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: A retrospective study. BMC Infect. Dis. 2013, 13, 1–5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  114. Salgado-Flores, L.; Horta-Padilla, I.; González-Varela, A. Cutaneous and deep mycosis caused by Talaromyces in Mexico. Microbiol. Infect. Dis. 2020, 4, 1–3. [Google Scholar] [CrossRef]
  115. Huang, X.; He, G.; Lu, S.; Liang, Y.; Xi, L. Role of Rhizomys pruinosus as a natural animal host of Penicillium marneffei in Guangdong, China. Microb. Biotechnol. 2015, 8, 659–664. [Google Scholar] [CrossRef] [PubMed]
  116. Li, X.; Zheng, Y.; Wu, F.; Mo, D.; Liang, G.; Yan, R.; Khader, J.A.; Wu, N.; Cao, C. Evaluation of quantitative real-time PCR and Platelia galactomannan assays for the diagnosis of disseminated Talaromyces marneffei infection. Med. Mycol. 2019, 58, 181–186. [Google Scholar] [CrossRef]
  117. Seyedmousavi, S.; Guillot, J.; Tolooe, A.; Verweij, P.E.; de Hoog, G.S. Neglected fungal zoonoses: Hidden threats to man and animals. Clin. Microbiol. Infect. 2015, 21, 416–425. [Google Scholar] [CrossRef] [Green Version]
Figure 1. Lifecycle and mode of transmission of zoonotic agent, sapronotic agent and environmental pathogen. (A) sapronotic agents/opportunists are non-transmissible; outbreak occurs following repeated infection from a common environmental source leading to sapronosis; (B) zoonotic agents/zoophilic pathogens depend on the host for feeding and transmission, which mainly occurs directly via contagious animal hosts; (C) environmental pathogen, feeding and sexuality is environmental, propagation via host, non-contagious. In (A,B), repeated events of transmission occur from the same host/environment as opposed to (C), where a single host is infected and spreads the infective agent in an environment; this is represented by the number of arrows connecting each host and environment. Adapted with permission from ref. [29]. Copyright 2022 Atlas Clinical Fungi web-version.
Figure 1. Lifecycle and mode of transmission of zoonotic agent, sapronotic agent and environmental pathogen. (A) sapronotic agents/opportunists are non-transmissible; outbreak occurs following repeated infection from a common environmental source leading to sapronosis; (B) zoonotic agents/zoophilic pathogens depend on the host for feeding and transmission, which mainly occurs directly via contagious animal hosts; (C) environmental pathogen, feeding and sexuality is environmental, propagation via host, non-contagious. In (A,B), repeated events of transmission occur from the same host/environment as opposed to (C), where a single host is infected and spreads the infective agent in an environment; this is represented by the number of arrows connecting each host and environment. Adapted with permission from ref. [29]. Copyright 2022 Atlas Clinical Fungi web-version.
Jof 08 00611 g001
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Carpouron, J.E.; de Hoog, S.; Gentekaki, E.; Hyde, K.D. Emerging Animal-Associated Fungal Diseases. J. Fungi 2022, 8, 611. https://doi.org/10.3390/jof8060611

AMA Style

Carpouron JE, de Hoog S, Gentekaki E, Hyde KD. Emerging Animal-Associated Fungal Diseases. Journal of Fungi. 2022; 8(6):611. https://doi.org/10.3390/jof8060611

Chicago/Turabian Style

Carpouron, Julia Eva, Sybren de Hoog, Eleni Gentekaki, and Kevin David Hyde. 2022. "Emerging Animal-Associated Fungal Diseases" Journal of Fungi 8, no. 6: 611. https://doi.org/10.3390/jof8060611

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop